Page 5 of 7 – SEC Filing
Cusip No. 767836109 13G Page
5 of 7 Pages
Item 1(a). Name of Issuer:
Ritter Pharmaceuticals, Inc. (the “Issuer”)
Item 1(b). Address of Issuer’s Principal Executive Offices:
1880 Century Park East, Suite 1000
Los Angeles, CA 90067
Item 2(a). Name of Persons Filing:
Knoll Capital Management LP (“KCMLP”)
Fred Knoll (“Knoll”)
Gakasa Holdings, LLC (“Gakasa”)
Item 2(b). Address of Principal Business Office or, if none,
Residence:
The principle business address for each of KCMLP, Knoll and
Gakasa is 5 East 44th Street, Suite 12, New York, NY 10017
Item 2(c). Citizenship:
KCMLP is a limited partnership formed and existing under the
laws of the State of Delaware.
Knoll is a citizen of the United States.
Gakasa is an LLC organized in state of Florida
Item 2(d). Title of Class of Securities:
This statement on Schedule 13G is being filed with respect to
Common Stock, $0.001 par value per share (the “Common Stock”) of the issuer.
Item 2(e). CUSIP Number:
767836109
Item 3. If this statement is filed pursuant to Rules 13d-1(b),
or 13d-2(b) or (c), check whether the person filing is a: Not applicable
(a) [__] Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o);
(b) [__] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c);
(c) [__] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c);
(d) [__] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e) [__] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) [__] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g) [__] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h) [__] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [__] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act
(15 U.S.C. 80a-3);
(j) [__] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k) [__] Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
Page 5 of 7
| Cusip No. 767836109 | 13G | Page 5 of 7 Pages |
| Item 1(a). | Name of Issuer: |
Ritter Pharmaceuticals, Inc. (the “Issuer”)
| Item 1(b). | Address of Issuer’s Principal Executive Offices: |
1880 Century Park East, Suite 1000
Los Angeles, CA 90067
| Item 2(a). | Name of Persons Filing: |
Knoll Capital Management LP (“KCMLP”)
Fred Knoll (“Knoll”)
Gakasa Holdings, LLC (“Gakasa”)
| Item 2(b). | Address of Principal Business Office or, if none, Residence: |
The principle business address for each of KCMLP, Knoll and
Gakasa is 5 East 44th Street, Suite 12, New York, NY 10017
| Item 2(c). | Citizenship: |
KCMLP is a limited partnership formed and existing under the
laws of the State of Delaware.
Knoll is a citizen of the United States.
Gakasa is an LLC organized in state of Florida
| Item 2(d). | Title of Class of Securities: |
This statement on Schedule 13G is being filed with respect to
Common Stock, $0.001 par value per share (the “Common Stock”) of the issuer.
| Item 2(e). | CUSIP Number: |
| 767836109 |
| Item 3. | If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: Not applicable |
| (a) | [__] | Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o); |
| (b) | [__] | Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c); |
| (c) | [__] | Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c); |
| (d) | [__] | Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
| (e) | [__] | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
| (f) | [__] | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); |
| (g) | [__] | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
| (h) | [__] | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| (i) | [__] | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); |
| (j) | [__] | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); |
| (k) | [__] | Group, in accordance with § 240.13d-1(b)(1)(ii)(K). |
| Page 5 of 7 |
Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)
Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)
Receive real-time insider trading and news alerts




